Search: onr:"swepub:oai:lup.lub.lu.se:e2b3e97e-5203-4fe5-9aa6-982df9dd5f36" > Switching clotting ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 02912naa a2200445 4500 | |
001 | oai:lup.lub.lu.se:e2b3e97e-5203-4fe5-9aa6-982df9dd5f36 | |
003 | SwePub | |
008 | 160401s2014 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/44702882 URI |
024 | 7 | a https://doi.org/10.1111/hae.122832 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Matino, D.4 aut |
245 | 1 0 | a Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity |
264 | c 2013-10-29 | |
264 | 1 | b Wiley,c 2014 |
520 | a The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small number of clinical studies that have addressed this question, and thus, the amount of objective information available to assess this association is limited. In this review, in addition to summarizing past evidence pertinent to this subject, we present the results of a complementary strategy, a Delphi analysis, to add to the considerations of product switching and FVIII immunogenicity. With the imminent arrival in the clinic of several new FVIII products, the haemophilia community must be prepared to collect prospectively controlled data to better address this important management issue. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
700 | 1 | a Lillicrap, D.4 aut |
700 | 1 | a Astermark, Janu Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)medf-jas |
700 | 1 | a Dolan, G.4 aut |
700 | 1 | a Kessler, C.4 aut |
700 | 1 | a Lambert, T.4 aut |
700 | 1 | a Makris, M.4 aut |
700 | 1 | a O'Donnell, J.4 aut |
700 | 1 | a Pipe, S.4 aut |
700 | 1 | a Santagostino, E.4 aut |
700 | 1 | a Saint-Remy, J. -M.4 aut |
700 | 1 | a Schramm, W.4 aut |
700 | 1 | a Iorio, A.4 aut |
710 | 2 | a Klinisk koagulationsmedicin, Malmöb Forskargrupper vid Lunds universitet4 org |
773 | 0 | t Haemophiliad : Wileyg 20:2, s. 200-206q 20:2<200-206x 1351-8216 |
856 | 4 | u http://dx.doi.org/10.1111/hae.12283y FULLTEXT |
856 | 4 | u http://deepblue.lib.umich.edu/bitstream/2027.42/106092/1/hae12283.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/4470288 |
856 | 4 8 | u https://doi.org/10.1111/hae.12283 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.